Benefits
Better Bioavailability than Resveratrol
Pterostilbene has 80% oral bioavailability vs ~20% for resveratrol — due to dimethylated structure resisting first-pass metabolism. Half-life ~7 hours (vs <1 hour for resveratrol). Functionally, pterostilbene may achieve and maintain therapeutic plasma levels more reliably.
Cognitive Function Support
Animal models show pterostilbene improves cognitive performance, particularly age-related cognitive decline. trial in adults showed mixed mood/cognitive effects with pterostilbene + grape extract; effect modest. Mechanism: SIRT1 activation, anti-inflammatory effects, neurogenesis support.
Cardiovascular Effects
trial showed pterostilbene reduced blood pressure modestly in adults with hyperlipidemia. Some evidence for cholesterol reduction. Anti-atherosclerotic mechanisms similar to resveratrol but potentially more bioavailable.
Anti-Inflammatory / Antioxidant
Reduces inflammatory markers, activates Nrf2 antioxidant pathway, modulates NF-κB. Broad anti-inflammatory profile basis for longevity applications.
SIRT1 Activation (Theoretical Longevity)
Like resveratrol, pterostilbene activates SIRT1 — sirtuin pathway involved in longevity. Better bioavailability theoretically translates to more reliable SIRT1 activation. Component of NMN/NR + sirtuin activator longevity stacks.
Mechanism of action
Resveratrol Analog with Better Pharmacokinetics
Dimethylated structure (vs resveratrol's hydroxyl groups) makes pterostilbene more lipophilic — better cell membrane penetration, slower metabolism, longer half-life. Same stilbene core mechanism with improved drug-like properties.
SIRT1 Activation
Activates SIRT1 deacetylase — relevant to longevity, mitochondrial biogenesis, glucose homeostasis. Same mechanism as resveratrol with potentially better bioavailability.
Nrf2 Antioxidant Pathway
Activates Nrf2 transcription factor, upregulating endogenous antioxidant enzymes (SOD, catalase, glutathione synthase). Adaptive antioxidant response.
PPAR-alpha Modulation
Modulates PPAR-alpha — nuclear receptor involved in lipid metabolism. May contribute to cholesterol and triglyceride effects.
Clinical trials
RCT of pterostilbene (125 mg BID) ± grape seed extract vs placebo in 80 adults with hyperlipidemia for 6-8 weeks.
80 hyperlipidemic adults.
Pterostilbene reduced blood pressure modestly; mixed lipid effects (some increase in LDL with pterostilbene alone — concerning); generally well-tolerated. Foundational human trial; results suggest pterostilbene effects are nuanced.
Phase 1 dose-finding study of pterostilbene in healthy adults — establishing pharmacokinetics, safety, tolerability up to 250 mg/day.
Healthy adults.
Pterostilbene well-tolerated up to 250 mg/day; bioavailability ~80% (vs ~20% resveratrol); half-life ~7 hours. Established safety profile and dosing range.